5-Amino-1MQ (50mg)

Small-molecule NNMT inhibitor. 5-Amino-1MQ is not a peptide at all. It is a small quinolinium molecule that blocks nicotinamide N-methyltransferase (NNMT), the enzyme that uses up nicotinamide and S-adenosylmethionine. It belongs in the same catalogue because it ships as a powder for reconstitution and is studied together with the metabolic peptides.

NNMT inhibition: selectivity and enzyme kinetics. Adipose metabolism: fat mass and adipocyte size in obese rodents. NAD+ salvage pathway: cellular NAD+ and the sparing of nicotinamide. Muscle regeneration: stem-cell activation studied in aged-muscle models. Rodent studies (Neelakantan et al., Biochem Pharmacol 2018) reported smaller adipocytes, lower body-fat mass and better metabolic markers in diet-induced obese mice, all without any change in food intake. Later work looked at how muscle stem cells function and at NAD+ levels in aged tissue.

In diet-induced obese mice the compound produced smaller adipocytes, lower body-fat mass and improved metabolic markers over several weeks, with food intake unchanged; no controlled human trials exist.

There are no human safety data. The rodent studies reported no toxicity at the doses used; because NNMT inhibition shifts the methylation balance, longer exposure is a theoretical concern.

In the published 5-Amino-1MQ research, the amounts used were 5 or 10 mg/kg in mouse, 24-month-old, muscle injury (unnamed nnmt inhibitor) (Neelakantan H et al. (2019)); 0.1–500 µM in cell culture, hela and hek-293 cells (5mq) (Akar S et al. (2021)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies 5-Amino-1MQ for in-vitro research and does not give dosing guidance for people.

5-Amino-1MQ is orally bioavailable in rodent studies, and here it ships as a powder for reconstitution, handled the same way as the peptides it sits alongside. Peptide Aus gives no usage guidance for people.

MOTS-c is a mitochondrial peptide that switches on AMPK, whereas 5-Amino-1MQ is a small molecule that blocks NNMT. Both are studied for metabolic flexibility by different routes.

SLU-PP-332 turns on ERR receptors to copy exercise signalling, while 5-Amino-1MQ blocks an enzyme that consumes NAD+ precursors.

AOD-9604 acts straight on adipocyte lipolysis; 5-Amino-1MQ works on adipocyte metabolism by way of NNMT.

Add about 2 mL of bacteriostatic water slowly down the inside of the vial and swirl gently; do not shake. 50mg in 2 mL gives 25 mg/mL. Refrigerate at 2–8 °C after reconstitution and use within 8–12 weeks. The calculator has this vial preset.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

The Therapeutic Goods Administration (TGA) has not registered 5-Amino-1MQ as a medicine in Australia, and it is not approved for human or veterinary use. Peptide Aus provides it as a research reagent for in-vitro laboratory work only. The Poisons Standard and the Therapeutic Goods Act govern the supply of any substance for human use in Australia, and lawful use of the material rests with the buyer. Anyone looking for a treatment should consult a doctor.

Directly from Peptide Aus, from Australian stock: 5-Amino-1MQ (50mg) is $109.99 AUD including GST. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.